Sign in

    Thomas Deal

    Vice President and Equity Research Analyst at Raymond James

    Thomas Deal is a Vice President and Equity Research Analyst at Raymond James, specializing in the coverage of technology and internet companies such as Alphabet, Meta Platforms, and Amazon. Known for his analytical rigor, he has consistently achieved above-average performance metrics, including a 68% success rate and an average annualized return of 10.5% on his stock recommendations as reported by independent analyst ranking platforms. Deal began his career in equity research in 2012 after earning his CFA designation, previously serving at Stifel Nicolaus prior to joining Raymond James in 2018. He is registered with FINRA, holds a Series 7 and 63 securities license, and has been recognized for his comprehensive industry insights and investor guidance.

    Thomas Deal's questions to Scholar Rock Holding (SRRK) leadership

    Thomas Deal's questions to Scholar Rock Holding (SRRK) leadership • Q2 2025

    Question

    Thomas Deal, on for Martin Auster at Raymond James, asked about the expected enrollment timeline for the OPAL trial in children under two and the significance of this market expansion.

    Answer

    President of R&D Akshay Vaishnaw confirmed OPAL enrollment will begin in Q3 2025 and that guidance on completion will follow once momentum builds. He highlighted that while important, the immediate and larger opportunity is the prevalent population of over 35,000 patients aged two and older who could benefit from apitigramab.

    Ask Fintool Equity Research AI